(NASDAQ: MOR) Morphosys Ag's forecast annual revenue growth rate of 5.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.46%.
Morphosys Ag's revenue in 2023 is $311,534,465.On average, 2 Wall Street analysts forecast MOR's revenue for 2023 to be $8,788,674,814, with the lowest MOR revenue forecast at $8,729,077,001, and the highest MOR revenue forecast at $8,848,272,627. On average, 2 Wall Street analysts forecast MOR's revenue for 2024 to be $9,669,702,331, with the lowest MOR revenue forecast at $9,096,796,533, and the highest MOR revenue forecast at $10,242,608,129.
In 2025, MOR is forecast to generate $17,075,064,328 in revenue, with the lowest revenue forecast at $13,952,939,967 and the highest revenue forecast at $20,197,222,921.